COSMO Pharmaceuticals SA (0RGI) - Total Liabilities
Based on the latest financial reports, COSMO Pharmaceuticals SA (0RGI) has total liabilities worth £143.35 Million GBP (≈ $192.51 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
COSMO Pharmaceuticals SA - Total Liabilities Trend (2004–2024)
This chart illustrates how COSMO Pharmaceuticals SA's total liabilities have evolved over time, based on quarterly financial data. See COSMO Pharmaceuticals SA working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
COSMO Pharmaceuticals SA Competitors by Total Liabilities
The table below lists competitors of COSMO Pharmaceuticals SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adaptive Plasma Technology Corp
KQ:089970
|
Korea | ₩51.39 Billion |
|
Orchid Island Capital Inc.
NYSE:ORC
|
USA | $11.28 Billion |
|
IMMUNOCORE HLDGS ADS/1
F:6YG
|
Germany | €686.24 Million |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥1.65 Billion |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
China | CN¥1.98 Billion |
|
CTS Corporation
NYSE:CTS
|
USA | $242.72 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥1.28 Billion |
|
Ascletis Pharma Inc
F:2VJ
|
Germany | €132.26 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down COSMO Pharmaceuticals SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see COSMO Pharmaceuticals SA market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COSMO Pharmaceuticals SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COSMO Pharmaceuticals SA (2004–2024)
The table below shows the annual total liabilities of COSMO Pharmaceuticals SA from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | £141.68 Million ≈ $190.26 Million |
+13.40% |
| 2023-12-31 | £124.94 Million ≈ $167.79 Million |
-57.76% |
| 2022-12-31 | £295.80 Million ≈ $397.24 Million |
+1.00% |
| 2021-12-31 | £292.88 Million ≈ $393.32 Million |
+49.40% |
| 2020-12-31 | £196.04 Million ≈ $263.26 Million |
+2.41% |
| 2019-12-31 | £191.43 Million ≈ $257.07 Million |
+5.86% |
| 2018-12-31 | £180.83 Million ≈ $242.84 Million |
+549.14% |
| 2017-12-31 | £27.86 Million ≈ $37.41 Million |
-0.21% |
| 2016-12-31 | £27.92 Million ≈ $37.49 Million |
-18.60% |
| 2015-12-31 | £34.30 Million ≈ $46.06 Million |
-53.23% |
| 2014-12-31 | £73.33 Million ≈ $98.48 Million |
+220.94% |
| 2013-12-31 | £22.85 Million ≈ $30.68 Million |
-16.13% |
| 2012-12-31 | £27.24 Million ≈ $36.59 Million |
+86.55% |
| 2011-12-31 | £14.60 Million ≈ $19.61 Million |
-56.35% |
| 2010-12-31 | £33.46 Million ≈ $44.93 Million |
+186.73% |
| 2009-12-31 | £11.67 Million ≈ $15.67 Million |
-19.68% |
| 2008-12-31 | £14.53 Million ≈ $19.51 Million |
+20.26% |
| 2007-12-31 | £12.08 Million ≈ $16.22 Million |
-33.86% |
| 2006-12-31 | £18.27 Million ≈ $24.53 Million |
-33.77% |
| 2005-12-31 | £27.58 Million ≈ $37.04 Million |
+13.30% |
| 2004-12-31 | £24.34 Million ≈ $32.69 Million |
-- |
About COSMO Pharmaceuticals SA
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more